We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+7.15%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.94B
AUM Growth
-$464M
Cap. Flow
-$553M
Cap. Flow %
-18.83%
Top 10 Hldgs %
35.63%
Holding
94
New
11
Increased
10
Reduced
24
Closed
23

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$66.6M
2
JNJ icon
Johnson & Johnson
JNJ
+$53.2M
3
IRTC icon
iRhythm Holdings
IRTC
+$48.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.4M
5
CAH icon
Cardinal Health
CAH
+$31.4M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$57.5M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$51.2M
3
HCA icon
HCA Healthcare
HCA
+$47.7M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$43.2M
5
GILD icon
Gilead Sciences
GILD
+$40.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.07%
2 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$46.3M 1.58%
315,449
+14,904
+5% +$2.31M
SNDX icon
27
Syndax Pharmaceuticals
SNDX
$1.7B
$46M 1.57%
2,103,512
+246,774
+13% +$4.56M
AZN icon
28
AstraZeneca
AZN
$245B
$45.8M 1.56%
392,874
– –
MCK icon
29
McKesson
MCK
$96.8B
$44M 1.5%
177,000
-172,181
-49% -$37.8M
WAT icon
30
Waters Corp
WAT
$36.8B
$43.8M 1.49%
117,634
– –
THC icon
31
Tenet Healthcare
THC
$20.1B
$43M 1.46%
525,927
-141,146
-21% -$10.3M
CTLT
32
DELISTED
CATALENT, INC.
CTLT
$41.8M 1.42%
326,700
+148,900
+84% +$19.1M
OEF icon
33
CALL
iShares S&P 100 ETF
OEF
$20.1B
$41.6M 1.42%
+272,800
New +$57.8M
SGEN
34
DELISTED
Seagen Inc. Common Stock
SGEN
$41.5M 1.41%
268,527
-96,103
-26% -$16.1M
TMO icon
35
Thermo Fisher Scientific
TMO
$213B
$41.5M 1.41%
62,143
-9,299
-13% -$5.81M
BMRN icon
36
BioMarin Pharmaceuticals
BMRN
$11.6B
$41.1M 1.4%
+464,940
New +$38.4M
NVRO
37
DELISTED
NEVRO CORP.
NVRO
$39.3M 1.34%
485,135
+92,349
+24% +$9.25M
NBIX icon
38
Neurocrine Biosciences
NBIX
$16.7B
$33.6M 1.14%
394,058
-470,021
-54% -$43.2M
JNCE
39
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$33.2M 1.13%
3,972,868
+124,046
+3% +$1.02M
CAH icon
40
Cardinal Health
CAH
$55.2B
$32.9M 1.12%
+639,783
New +$31.4M
HRTX icon
41
Heron Therapeutics
HRTX
$96.8M
$32.1M 1.09%
3,512,348
+518,802
+17% +$5.3M
XNTK icon
42
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.11B
$27.6M 0.94%
+246,100
New +$40.9M
SOPH icon
43
SOPHiA GENETICS
SOPH
$477M
$27.5M 0.94%
1,952,152
-70,400
-3% -$1.04M
KRTX
44
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$23.2M 0.79%
177,091
– –
MOH icon
45
Molina Healthcare
MOH
$10.2B
$22.3M 0.76%
70,088
– –
NTLA icon
46
Intellia Therapeutics
NTLA
$1.5B
$21.1M 0.72%
178,222
– –
ELV icon
47
Elevance Health
ELV
$83B
$19.8M 0.67%
+42,734
New +$18M
CANO
48
DELISTED
Cano Health, Inc.
CANO
$17.1M 0.58%
19,146
-1,797
-9% -$1.89M
ISEE
49
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$16.8M 0.57%
1,005,216
-132,896
-12% -$2.18M
NVAX icon
50
Novavax
NVAX
$1.22B
$12.7M 0.43%
88,663
-108,545
-55% -$18.7M
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q4 2021 Portfolio in Review

As of Q4 2021, PFM Health Sciences held 94 positions worth $2.94B, down 14% from $3.4B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

PFM Health Sciences withdrew a net $553M in Q4 2021, closing 23 positions and reducing 24 holdings. Its most notable exit was Allogene Therapeutics, an estimated $19.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 86% a quarter earlier, followed by Financials.

Against the trend, PFM Health Sciences opened a new position in Pfizer worth $79.3M.

  • PFM Health Sciences's largest Q4 2021 buy was Pfizer: 1,343,384 shares worth $79.3M.
  • PFM Health Sciences added most to CATALENT, INC. in Q4 2021, an estimated $19.1M increase.
  • PFM Health Sciences's biggest Q4 2021 reduction was Eli Lilly, cutting an estimated $57.5M.
  • PFM Health Sciences fully exited Allogene Therapeutics in Q4 2021, selling an estimated $19.9M.
  • PFM Health Sciences's ten largest holdings make up 36% of its $2.94B portfolio in Q4 2021.
  • PFM Health Sciences opened 11 new positions and closed 23 in Q4 2021.
  • PFM Health Sciences's portfolio value fell 14% quarter-over-quarter to $2.94B.

Based on PFM Health Sciences's 13F filing for Q4 2021, filed 14 Feb 2022.